FDA advises on the risk of dental problems from the use of the opioid addiction drug buprenorphine

Signs can be seen outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, USA on August 29, 2020. REUTERS / Andrew Kelly

Register now for FREE unlimited access to Reuters.com

to register

Jan. 12 (Reuters) – The U.S. health agency on Wednesday warned patients and prescribers of the risk of potential dental problems arising from using buprenorphine drugs to treat opioid addiction and pain.

The Food and Drug Administration said that treating opioid addiction in patients with no history of dental problems causes tooth decay, infection and, in some cases, complete tooth loss. (https://bit.ly/3fiJEj8)

Buprenorphine medicines that have been linked to dental problems are tablets that dissolve under the tongue and films that are placed on the inside of the cheek.

Register now for FREE unlimited access to Reuters.com

to register

The FDA, which approved buprenorphine as a tablet in 2002 and as a film in 2015, said patients can reduce their risk by taking preventative measures, including waiting at least an hour before brushing their teeth after using the product.

Buprenorphine products approved by the regulatory authority include Zubsolv from Orexo and Suboclade from Indivior (INDV.L).

The benefits of buprenorphine medication for opioid use disorders and pain clearly outweigh the risks and are important tools in treating these conditions, according to the FDA.

Register now for FREE unlimited access to Reuters.com

to register

Reporting from Leroy Leo; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.

http://www.viaspace.com/includes/magpierss-0.72/scripts/magpie_slashbox.php?rss_url=http://feeds.feedburner.com/SyndicationSite

Comments are closed.